Another multi-TAA peptide vaccine approach directed against PRAME, NY-ESO-1, MAGE-A3, and WT-1 in combination with 5′-aza-2′-deoxycytidine is currently in phase I trial in patients with myelodysplastic syndrome and acute myeloid leukemia (NCT02750995). The gene discussed is PRAME; the disease is acute myeloid leukemia.